Industry Standard Research (ISR) today announced the release of The State of Biomarkers in Drug Development report. 44 pharmaceutical and biotechnology professionals provided their strategies, insights, and predictions in this snapshot of a rapidly evolving market. In total, 37 significant pharma and biotech companies contributed to this endeavor.
“With the scarcity of experts in the field of biomarkers, we were excited to capture the perspectives of 44 in our research and we expect that the industry will benefit tremendously from their candid insights.”
"There is a real desire within our industry for a better understanding of how biomarkers are being incorporated into clinical trials. In particular, drug developers - operating in a vacuum - are unsure of their own strategies and progress and CROs are wondering how much to invest in expensive technologies and capabilities because they do not yet understand how rapidly these technologies will be adopted by their customers," explained Kevin Olson, President, ISR. Olson went on to state: "This report shines a spotlight on developers' current and future adoption of six categories of biomarkers, including: Surrogate Biomarkers, Toxicity Biomarkers, Diagnostic Biomarkers, Early Detection / Screening Biomarkers, Prognostic Biomarkers, and Predictive Biomarkers. Because this technology is advancing so rapidly, we felt it was important to not only capture current use of these biomarkers, but also to estimate the increase in use out to 2013."
In addition, the report details current and future adoption of several specific biomarker technologies including Bioinformatics and Systems Biology, Genomics, Glycomics, Histomics, Imaging, Metabolomics, and Proteomics. It also uncovers at what stages of a product's development the drug developers typically formulate their biomarkers strategy; the percent of products in the pipeline with biomarker strategies; the likelihood of outsourcing biomarker development work; and the drivers and barriers to companies expanding their biomarker strategies.
Kevin Olson, President ISR, further explains:
"With the scarcity of experts in the field of biomarkers, we were excited to capture the perspectives of 44 in our research and we expect that the industry will benefit tremendously from their candid insights."
Source: Industry Standard Research